

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



1 September 2014

UBI receives cash payment of \$8M from the R&D tax refund

Universal Biosensors (ASX:UBI) today announced it has received \$8M in cash under the R&D tax incentive relating to the Company's FY13 R&D expenses, following the lodgement of the Company's annual income tax return.

The Research and Development tax incentive provides a tax offset for eligible R&D activities and is targeted toward R&D that benefits Australia. UBI became eligible for the R&D tax rebate for the first time in 2013. It is expected that R&D expenses incurred in the current financial year will also be eligible for the R&D tax incentive.

Paul Wright, CEO of Universal Biosensors, said: *"We are very pleased to receive the \$8M tax incentive from the Australian Government. This money bolsters our cash reserves and provides non-dilutive funding for our innovative pipeline of point-of-care diagnostics products."*

Enquiries:

Paul Wright +61 3 9213 9000

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to <http://www.universalbiosensors.com/announcements.html>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.